JP2019518046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518046A5 JP2019518046A5 JP2018565675A JP2018565675A JP2019518046A5 JP 2019518046 A5 JP2019518046 A5 JP 2019518046A5 JP 2018565675 A JP2018565675 A JP 2018565675A JP 2018565675 A JP2018565675 A JP 2018565675A JP 2019518046 A5 JP2019518046 A5 JP 2019518046A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ring
- alkyl
- aromatic
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 201000008827 tuberculosis Diseases 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229910052717 sulfur Chemical group 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000002365 anti-tubercular Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- -1 eg fluoro atoms) Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174719 | 2016-06-16 | ||
| EP16174719.1 | 2016-06-16 | ||
| PCT/EP2017/064652 WO2017216281A1 (en) | 2016-06-16 | 2017-06-15 | Heterocyclic compounds as antibacterials |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518046A JP2019518046A (ja) | 2019-06-27 |
| JP2019518046A5 true JP2019518046A5 (OSRAM) | 2020-08-13 |
Family
ID=56132837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565675A Pending JP2019518046A (ja) | 2016-06-16 | 2017-06-15 | 抗菌薬としての複素環式化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11179396B2 (OSRAM) |
| EP (1) | EP3472158A1 (OSRAM) |
| JP (1) | JP2019518046A (OSRAM) |
| KR (1) | KR20190017948A (OSRAM) |
| CN (1) | CN109476657A (OSRAM) |
| AU (1) | AU2017286368B2 (OSRAM) |
| BR (1) | BR112018076126A2 (OSRAM) |
| CA (1) | CA3026010A1 (OSRAM) |
| EA (1) | EA201990043A1 (OSRAM) |
| MA (1) | MA45377A (OSRAM) |
| MX (1) | MX2018015656A (OSRAM) |
| WO (1) | WO2017216281A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016287478B2 (en) | 2015-07-02 | 2021-10-21 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| JP7055378B2 (ja) | 2015-09-17 | 2022-04-18 | ユニバーシティ・オブ・ノートル・ダム・デュ・ラック | マイコバクテリア感染症に対して有用なベンジルアミン含有複素環化合物及び組成物 |
| AU2017286368B2 (en) | 2016-06-16 | 2021-02-25 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| CN110831630A (zh) | 2017-03-01 | 2020-02-21 | 爱尔兰詹森科学公司 | 组合疗法 |
| WO2019058393A1 (en) | 2017-09-22 | 2019-03-28 | Jubilant Biosys Limited | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD |
| FI3697785T3 (fi) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidatsopyridiiniyhdisteitä pad:n estäjinä |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| TWI861208B (zh) | 2019-09-10 | 2024-11-11 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物 |
| BR112022003799A2 (pt) | 2019-09-13 | 2022-05-24 | Janssen Sciences Ireland Unlimited Co | Compostos antibacterianos |
| US20220396586A1 (en) * | 2019-09-26 | 2022-12-15 | The Global Alliance For Tb Drug Development, Inc. | Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections |
| MX2022003816A (es) | 2019-09-30 | 2022-05-06 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| CA3149988A1 (en) | 2019-09-30 | 2021-04-08 | Jerome Emile Georges Guillemont | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS |
| AU2022237769A1 (en) | 2021-03-16 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3211592A1 (en) | 2021-03-17 | 2022-09-22 | Jerome Emile Georges Guillemont | Antibacterial compounds |
| JP2024509998A (ja) * | 2021-03-17 | 2024-03-05 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌化合物 |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| US20250034171A1 (en) | 2021-10-28 | 2025-01-30 | Janssen Sciences Ireland Unlimited Company | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952324A (en) | 1994-11-15 | 1999-09-14 | Pharmacia & Upjohn Company | Bicyclic oxazine and thiazine oxazolidinone antibacterials |
| CA2218088A1 (en) | 1995-05-11 | 1996-11-14 | Pharmacia & Upjohn Company | Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones |
| RS52431B (sr) | 2002-07-25 | 2013-02-28 | Janssen Pharmaceutica N.V. | Derivati hinolina i njihova upotreba kao mikobakterijskih inhibitora |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| EP2134713A2 (en) | 2006-12-20 | 2009-12-23 | Schering Corporation | Novel jnk inhibitors |
| CL2008001631A1 (es) | 2007-06-06 | 2009-01-02 | Smithkline Beecham Corp | Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| JP5613656B2 (ja) | 2008-03-26 | 2014-10-29 | グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント | 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール |
| EP2353008A2 (en) | 2008-09-22 | 2011-08-10 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| CA2748274A1 (en) | 2008-12-30 | 2010-07-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
| BR112012010752B1 (pt) | 2009-11-05 | 2021-07-20 | University Of Notre Dame Du Lac | Compostos imidazo[1,2-a]piridina |
| SG10201502109VA (en) * | 2010-03-18 | 2015-05-28 | Pasteur Institut Korea | Anti-infective compounds |
| KR20140093610A (ko) | 2011-04-21 | 2014-07-28 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| UY34301A (es) | 2011-09-01 | 2013-04-05 | Irm Llc | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit |
| PT2820008T (pt) | 2012-03-02 | 2017-05-05 | Genentech Inc | Amidas amido-espirocíclicas e derivados de sulfonamidas |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| EP2875029B8 (en) | 2012-07-18 | 2021-12-15 | University of Notre Dame du Lac | 5,5-heteroaromatic anti-infective compounds |
| KR102323873B1 (ko) * | 2012-08-10 | 2021-11-09 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 신규한 항균성 화합물 |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| US20160185774A1 (en) | 2013-08-02 | 2016-06-30 | Institut Pasteur Korea | Anti-Infective Compounds |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| CN107249691A (zh) | 2014-11-03 | 2017-10-13 | 加利福利亚大学董事会 | 用于肺结核治疗的多药疗法 |
| AU2016287478B2 (en) | 2015-07-02 | 2021-10-21 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| AU2017286368B2 (en) | 2016-06-16 | 2021-02-25 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| JP2019518050A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
| CN110831630A (zh) | 2017-03-01 | 2020-02-21 | 爱尔兰詹森科学公司 | 组合疗法 |
-
2017
- 2017-06-15 AU AU2017286368A patent/AU2017286368B2/en not_active Ceased
- 2017-06-15 CN CN201780037229.4A patent/CN109476657A/zh active Pending
- 2017-06-15 MX MX2018015656A patent/MX2018015656A/es unknown
- 2017-06-15 CA CA3026010A patent/CA3026010A1/en not_active Abandoned
- 2017-06-15 EA EA201990043A patent/EA201990043A1/ru unknown
- 2017-06-15 EP EP17729877.5A patent/EP3472158A1/en not_active Withdrawn
- 2017-06-15 US US16/309,725 patent/US11179396B2/en active Active
- 2017-06-15 BR BR112018076126-5A patent/BR112018076126A2/pt not_active Application Discontinuation
- 2017-06-15 MA MA045377A patent/MA45377A/fr unknown
- 2017-06-15 KR KR1020197000960A patent/KR20190017948A/ko not_active Ceased
- 2017-06-15 WO PCT/EP2017/064652 patent/WO2017216281A1/en not_active Ceased
- 2017-06-15 JP JP2018565675A patent/JP2019518046A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518046A5 (OSRAM) | ||
| JP2019518050A5 (OSRAM) | ||
| JP2018519302A5 (OSRAM) | ||
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| JP2018524339A5 (OSRAM) | ||
| JP2017524025A5 (OSRAM) | ||
| JP2014500295A5 (OSRAM) | ||
| JP2019526596A5 (OSRAM) | ||
| JP2017527532A5 (OSRAM) | ||
| JP2013532652A5 (OSRAM) | ||
| PT76336A (de) | Cephalosporinderivate und verfahren zu ihrer herstellung | |
| JP2019529444A5 (OSRAM) | ||
| JP2017510610A5 (OSRAM) | ||
| JP2020097577A5 (OSRAM) | ||
| CN108025191A (zh) | 治疗癌症的方法 | |
| JP2019527724A5 (OSRAM) | ||
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| NO156690C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanderivater. | |
| JP2013542267A5 (OSRAM) | ||
| JPWO2023099608A5 (OSRAM) | ||
| JPWO2021030556A5 (OSRAM) | ||
| JP2015522592A5 (OSRAM) | ||
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| JPWO2022250170A5 (OSRAM) | ||
| KR101536488B1 (ko) | 이미다졸 유도체, 그의 제조 방법 및 용도 |